Abstract
At the Memorial Sloan-Kettering Cancer Center (MSKCC) multiagent chemotherapy for the treatment of osteosarcoma (OS) was introduced by Dr. Gerald Rosen in 1973[1]. Rosen and Marcove developed the concept of an initial period of chemotherapy prior to definitive surgery of the primary tumor (neoadjuvant chemotherapy). The initial impetus for this strategy came from the need to create custom prostheses for limb-sparing surgery. Rosen and Huvos examined the tumors removed at definitive surgery for the degree of necrosis present following neoadjuvant chemotherapy [2]. They demonstrated a strong correlation between the histologically evaluated response and subsequent disease-free survival (DFS).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosen G, Murphy ML, Huvos AG, et al. Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37:1–11, 1976.
Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230, 1982.
Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163–2177, 1979.
Rosen G. Pre-operative (neo-adjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 8:659–664, 1985.
Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337, 1988.
Provisor A, Nachman J, Krailo M, et al. Treatment of nonmetastatic osteogenic sarcoma (OS) of the extremities with pre-and post-operative chemotherapy. Proc Am Soc Clin Oncol 6:217, 1987.
Meyers P, Casper E, Huvos A, et al. Osteogenic sarcoma (OS): a randomized trial of intensive pre-operative (pre-op) chemotherapy (chemo) vs. chemo guided by histologic response (HR) to pre-op chemo. Proc Am Soc Clin Oncol 10:318, 1991.
Krailo M, Ertel E, Makley J, et al. A randomized trial comparing high dose methotrexate with moderate dose methotrexate as components of adjuvant chemotherapy in childhood non-metastatic osteosarcoma. Med Ped Oncol 15:69–77, 1987.
Mosende C, Gutierrez M, Caparros B, et al. Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer 40:2779–2786, 1977.
Pratt CB, Epelman S, Jaffe N. Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients. Cancer Treat Rep 71:421–423, 1987.
Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 66:1703–1710, 1990.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Meyers, P.A., Heller, G., Vlamis, V. (1993). Osteosarcoma of the extremities: Chemotherapy experience at Memorial Sloan-Kettering. In: Humphrey, G.B., Koops, H.S., Molenaar, W.M., Postma, A. (eds) Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Cancer Treatment and Research, vol 62. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3518-8_37
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3518-8_37
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6561-7
Online ISBN: 978-1-4615-3518-8
eBook Packages: Springer Book Archive